● Recruiting

CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound

Condition: Cirrhosis · Portal Hypertension Related to Cirrhosis · Sponsor: University Hospital, Clermont-Ferrand

PhaseNA

Planned participants30

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to assess the efficacy after one month of treatment with Carvedilol (12.5 mg daily) in primary prophylaxis of digestive haemorrhage due to portal hypertension in cirrhosis, by endoscopic ultrasound-guided portal pressure gradient measurement.

This description comes directly from the study's public registry record.

Talk to the study team

Lise Laclautre · +33473754963 · promo_internet_drci@chu-clermontferrand.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Lise Laclautre	Clermont-Ferrand, France	Not Yet Recruiting
Chu Estaing Medecine Digestive Et Hepatobiliaire	Clermont-Ferrand, France	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06861075